🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Rachel E. Sanborn

Cancer Institute (WIA)

ORCID: 0000-0003-0542-6054

Also affiliated with Providence Portland Medical Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: “Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors”.

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005147
N/A
1.7DataRank · unranked
66 citations

Michael J. Pishvaian, Margaret K. Callahan, Amy Weise, Branimir I. Šikić, Osama E. Rahma +19 more

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002446
N/A
1.0DataRank · unranked
26 citations

Omid Hamid, Elisabeth G.E. de Vries, Patrick A. Ott, Javier García-Corbacho, Valentina Boni +8 more

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies

Journal of Hematology & Oncology(2025)10.1186/s13045-025-01705-2
N/A
0.477DataRank · unranked
23 citations

Jordi Rodon, Yan Liang, Xinhong Wu, Qun Li, Lihua Song +23 more

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

UNC Libraries(2020)10.17615/74ry-7003
N/A
0DataRank · unranked
0 citations

Editta Baldini, Pierre-Jean Souquet, Grace K. Dy, Ariel López-Chávez, Federico Cappuzzo +25 more

BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape

npj Precision Oncology(2024)10.1038/s41698-024-00552-7
N/A
0DataRank · unranked
38 citations

Rachel E. Sanborn, Marcelo V. Negrão, Aria Vaishnavi, Egbert F. Smit, David Planchard